Imfinzi demonstrated unprecedented survival in unresectable, Stage III non-small cell lung cancer with an estimated 50% of patients surviving four years
PACIFIC Phase III trial data at ESMO also showed an estimated 35% of non-small cell lung cancer patients treated with Imfinzi had not progressed after four years CASPIAN Phase III trial data also at ESMO underscored long-term benefit in a proportion of patients with extensive-stage small cell lung cancerUpdated results from the PACIFIC Phase III trial showed AstraZeneca’s Imfinzi (durvalumab) demonstrated a sustained, clinically meaningful overall survival (OS) and progression-free survival (PFS) benefit in patients with unresectable, Stage III non-small cell lung cancer (NSCLC)